Related Experiment Video
Updated: Aug 9, 2026

Strategies for Tracking Anastasis, A Cell Survival Phenomenon that Reverses Apoptosis
Published on: February 16, 2015
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of
M A Grotzer1, A Eggert, T J Zuzak
1Division of Oncology, The Children's Hospital of Philadelphia, Pennsylvania 19104, USA.
Abstract:
TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. To characterize the TRAIL death pathway in childhood primitive neuroectodermal brain tumor (PNET), 8 human PNET cell lines were tested for TRAIL-induced apoptosis. TRAIL-sensitivity of the PNET cell lines was correlated with mRNA expression levels of TRAIL, its agonistic (TRAIL-R1, TRAIL-R2) and antagonistic (TRAIL-R3, TRAIL-R4) receptors, cellular FLICE-like inhibitory protein (cFLIP), caspase-3 and caspase-8. Three of 8 PNET cell lines tested were susceptible to TRAIL-induced apoptosis. Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cFLIP. However, all TRAIL-sensitive PNET cell lines expressed caspase-8 mRNA and protein, while none of the five TRAIL-resistant PNET cell lines expressed caspase-8 protein. Treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored mRNA expression of caspase-8 and TRAIL-sensitivity in formerly TRAIL-resistant PNET cells, suggesting that gene methylation inhibits caspase-8 transcription in these cells. We conclude, that loss of caspase-8 mRNA is an important mechanism of TRAIL-resistance in PNET cells. Treatment with recombinant soluble TRAIL, possibly in combination with methyltransferase inhibitors, represents a promising therapeutic approach for PNET that deserves further investigation.
Insights
Childhood primitive neuroectodermal brain tumors (PNETs) can be targeted with TNF-related apoptosis-inducing ligand (TRAIL). TRAIL-resistance in PNETs is linked to a lack of caspase-8, which can be reversed with methyltransferase inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various solid tumors but not normal tissues.
- Childhood primitive neuroectodermal brain tumors (PNETs) are a significant challenge in pediatric oncology.
Purpose of the Study:
- To investigate the TRAIL death pathway and its therapeutic potential in human PNET cell lines.
- To identify mechanisms of TRAIL-resistance in PNETs.
Main Methods:
- Assessed TRAIL-induced apoptosis in 8 human PNET cell lines.
- Correlated TRAIL sensitivity with mRNA expression of TRAIL, its receptors (TRAIL-R1-R4), cFLIP, caspase-3, and caspase-8.
- Investigated the effect of 5-aza-2'-deoxycytidine on TRAIL-resistant PNET cells.
Main Results:
- Three of 8 PNET cell lines were sensitive to TRAIL-induced apoptosis.
- TRAIL sensitivity did not correlate with TRAIL receptor or cFLIP expression.
- TRAIL-sensitive PNETs expressed caspase-8 (mRNA and protein), while resistant PNETs lacked caspase-8 protein.
- 5-aza-2'-deoxycytidine restored caspase-8 expression and TRAIL sensitivity in resistant PNET cells, suggesting epigenetic regulation.
Conclusions:
- Loss of caspase-8 mRNA expression is a key mechanism of TRAIL-resistance in PNET cells.
- Recombinant soluble TRAIL, potentially combined with methyltransferase inhibitors, shows promise for PNET therapy.
- Epigenetic silencing of caspase-8 may be a targetable vulnerability in PNET treatment.
Related Concept Videos
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy

